Novartis spends on deals to offset patent losses

Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 billion (£9 billion) cash deal for Avidity Biosciences, a biopharma with a new class of therapeutics that allows antibody-targeted delivery of RNA.